ArticleScientific reports2025
Evaluation of salivary ceruloplasmin for the diagnosis of Wilson's disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Analysis of oral health status and factors influencing DMFT scores in patients with Wilson's disease: a cross-sectional study.BMC oral health · 2026Article
- Dental Amalgam and Oral Biological Responses: A Narrative Review of Current Evidence.Dentistry journal · 2026Review
- Recent advances in research on high-frequency mutations in the ATP7B gene associated with Wilson disease in the Chinese population: from genetic evolution to precision medicine.Frontiers in molecular biosciences · 2026Review
- Integrated proteomics and single-cell transcriptomics reveal potential therapeutic targets in Wilson's disease patients.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The serum ceruloplasmin assay is the most commonly used test for diagnosing Wilson's disease (WD). Despite the utility of non-invasive tests for diagnosing WD, no such tests have been developed. Therefore, we aimed to identify a safe and non-invasive assay and determine the factors associated with salivary ceruloplasmin. The sample comprised 167 participants: 130 patients with WD (experimental group) and 37 individuals without WD (control group). Salivary ceruloplasmin's diagnostic performance was assessed using a receiver operating characteristic curve analysis, and the diagnostic thresholds were determined. The Mann-Whitney U test for independent samples was used to compare intergroup variability between the control and WD groups. We used Pearson's correlation coefficient to determine intergroup correlations between the blood and salivary ceruloplasmin levels of patients with WD. Salivary ceruloplasmin levels were significantly lower in the WD group than in the control group. Serum and salivary ceruloplasmin levels were positively correlated. The area under the curve for salivary ceruloplasmin was 0.9977. The critical value of salivary ceruloplasmin was 8.885 ng/mL, with a sensitivity of 99.23% and specificity of 100%. Evidently, salivary ceruloplasmin has substantial diagnostic value. Therefore, saliva analysis can be used as a non-invasive alternative to serum analysis for diagnosing WD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.